SHANGHAI, July 2, 2024 /PRNewswire/ -- Pulnovo Medical
Limited, a globally recognized device pioneer in the treatment of
Pulmonary Hypertension (PH) and Heart Failure (HF), is pleased to
announce the successful initiation and
first two patients enrollment for its
global multicenter clinical study exploring the percutaneous
pulmonary artery denervation (PADN) treatment for pulmonary
hypertension associated with left heart disease. This
landmark event took place at Centro Hospitalar Universitário de
Lisboa Central - Hospital de Santa
Marta in Portugal, marking
the beginning of Pulnovo Medical's innovative product deployment on
a global scale.
Under the guidance of Professor Hang
Zhang from Nanjing Medical University Affiliated Nanjing
Hospital, Prof. Ruben Ramos and his
team successfully performed the PADN procedure on two patients. The
procedure was smooth, the devices easy to operate, and the results
were excellent. The Portuguese medical team was impressed by the
PADN technology's safety and efficacy, as demonstrated by many
years of data. Clinical parameters showed promising results
when using PADN technology. The products' comprehensive design and
high-precision algorithm control significantly ensured stable
energy output and effective surgical results.
Prof. Ruben Ramos said,
"PADN technology shows great potential in treating pulmonary
hypertension associated with left heart disease. We are delighted
to be the first in Europe to
participate in this global clinical study. Our team is confident in
this project and looks forward to bringing more treatment options
to European pulmonary hypertension patients through this study.
PADN is not only a new treatment method but also brings new hope to
patients suffering from pulmonary hypertension."
Jessie
Lian,Pulnovo Medical's CEO said,
"The PADN global multicenter clinical study is one of our
key projects dedicated to innovative treatment technologies in the
cardiovascular field. As an emerging treatment, PADN has enormous
potential and prospects. The post-operative results of the first
overseas application of PADN reflect the academic
borderlessness of the moment. In the future, we will continue to
firmly advance our global business, steadily promoting the teaching
and learning of PADN technology. "
Cynthia Chen, Pulnovo
Medical's Chairlady said, "We are proud to have
successfully completed the first enrollment in the
European multicenter clinical study of PADN in Portugal, marking the acceleration of our
technology's global progress. We will continue to promote the
global application of PADN, allowing more patients to benefit from
this innovative therapy."
View original
content:https://www.prnewswire.co.uk/news-releases/pulnovo-medical-announces-first-enrollment-in-portugal-for-global-clinical-study-of-padn-technology-in-treating-pulmonary-hypertension-associated-with-left-heart-disease-302187950.html